Keen Vision Acquisition CORP 8-K filings

Keen Vision Acquisition Corporation announced its securities will be suspended and delisted from Nasdaq due to non-compliance with listing rules, including the deadline for business combinations and minimum public float requirements.

Keen Vision Acquisition Corporation has issued a $120,000 promissory note to its sponsor to extend the deadline for completing a business combination to July 27, 2026.

Keen Vision Acquisition Corporation has amended its letter of intent with Medera Inc., extending the deadline to negotiate and execute a replacement merger agreement to April 30, 2026.

Keen Vision Acquisition Corporation terminates prior merger agreement with Medera Inc. and enters new Letter of Intent for a revised business combination with Novoheart Group Limited.

Keen Vision Acquisition Corporation secured shareholder approval to extend its business combination deadline to July 27, 2026, but saw 3.78 million shares redeemed.

Keen Vision Acquisition Corporation secured a $144,670.38 promissory note from its sponsor to extend its business combination deadline to January 27, 2026.

Keen Vision Acquisition Corporation secured a $144,670.38 unsecured promissory note from its sponsor to extend the deadline for completing a business combination.

Keen Vision Acquisition Corporation secured a $144,670.38 promissory note from its sponsor to extend the business combination deadline to November 27, 2025.

Keen Vision Acquisition Corporation secured a $144,670.38 promissory note from its sponsor to extend its business combination deadline to October 27, 2025.

Keen Vision Acquisition Corporation's sponsor has wired $144,670.38 to the trust account for public shareholders.

Keen Vision Acquisition Corporation secured a $144,670.38 promissory note from its sponsor, KVC Sponsor LLC, to extend its business combination deadline.

Keen Vision Acquisition Corporation secured shareholder approval to extend its business combination deadline to January 27, 2026, supported by a $144,670.38 promissory note from its sponsor, despite 1.58 million shares being tendered for redemption.

Keen Vision Acquisition Corporation has obtained a $200,000 unsecured promissory note from its sponsor, KVC Sponsor LLC, to extend its deadline for completing a business combination until July 27, 2025.

Keen Vision Acquisition Corporation (KVAC) has secured a $200,000 unsecured promissory note from its sponsor, KVC Sponsor LLC, to extend its deadline for completing a business combination to June 27, 2025.

Keen Vision Acquisition Corporation obtained a $200,000 unsecured loan from its sponsor to extend the deadline for completing a business combination.

Keen Vision Acquisition Corporation issued a $200,000 promissory note to its sponsor, KVC Sponsor LLC, to extend the deadline for completing a business combination.

Keen Vision Acquisition Corporation issued a $200,000 promissory note to its sponsor, KVC Sponsor LLC, to extend the deadline for completing a business combination to March 27, 2025.

Keen Vision Acquisition Corporation obtained a $200,000 unsecured loan from its sponsor to extend the deadline for completing a business combination.

Keen Vision Acquisition Corporation issued a $200,000 promissory note to its sponsor, KVC Sponsor LLC, to extend the deadline for completing a business combination to January 27, 2025.

Keen Vision Acquisition Corporation issued a $200,000 promissory note to its sponsor to extend the deadline for completing a business combination.

Keen Vision Acquisition Corporation issued a $200,000 promissory note to its sponsor and extended its business combination deadline to July 27, 2025, with monthly extension options.

Keen Vision Acquisition Corporation adjourned its annual general meeting to October 25, 2024, without conducting any business other than approving the adjournment.

Medera, a clinical-stage biotech firm, will list on NASDAQ via a merger with Keen Vision Acquisition Corporation, aiming to advance its cardiovascular disease therapies.

Keen Vision Acquisition Corporation has signed a non-binding letter of intent with a Boston-based clinical stage biopharmaceutical company for a potential business combination.

Keen Vision Acquisition Corporation reports the resignation of director Ronald Adolphus Li and the appointment of William Chu to the board, effective immediately on March 13, 2024.